Computerized Fluidic System and Methods of Use for Characterization of Molecular Networks in Complex Systems with Automated Sampling, Data Collection, Assays and Data Analytics
20220246243 · 2022-08-04
Inventors
Cpc classification
G16H10/40
PHYSICS
G16B45/00
PHYSICS
G16H50/20
PHYSICS
G16B40/10
PHYSICS
International classification
G16B40/10
PHYSICS
G01N33/50
PHYSICS
Abstract
Our biology, in health and disease, is characterized by multiple cooperating molecules in highly regulated networks. Derangements of these networks can identify imminent severe worsening of disease, known as “the tipping point”. Identifying this change early has been shown to predict worsening, but also, to reveal opportunities for specific molecular therapies to halt disease progression. Unfortunately, there are no tools currently available to characterize molecular networks in humans or to see important changes coming. The current invention is a computer system linked to computer networks and data sources, to micro- and milli-fluidic sampling and assay devices. It uses advanced data analytics to examine the available data and to learn how to recognize impending trouble at a time when there are recognizable processes to block, and before it is too late for treatment.
Claims
1. An automated computer and fluidic system that characterizes molecular networks in complex systems using data analytics and contextual data to optimize sample collection strategies, to predict important molecular changes, and to confirm them with molecular measurements on obtained samples, comprising: a networked computer that gathers contextual data and assay results and updates predictive models; automated fluidic sampling components that store samples for later assays, and also run real time assays; software controlled valves that split sample stream(s) among storage and assay devices; and software that creates and stores contextually annotated molecular dynamics databases and constructs an annotated timeline with events of interest and decisions made, for teaching and research purposes.
2. The system of claim 1 further comprising: Networked computers for obtaining contextual data that may include, but not be limited to, connections with databases, the edge computing environment, cloud computing, Internet of Things (IoT) devices, smart devices, smart phones, and sensors for data input; and Other network connections to smart devices may include, but not be limited to, patient support devices such as mechanical ventilators, intravenous pumps, cardiac monitors, pulse oximeters, dialysis and extracorporeal membrane oxygenators, hospital bed sensors, patient attached sensors, cardiac assist devices.
3. The system of claim 1 further comprising: data analytic approaches to be tested that may include, but not be limited to, artificial intelligence algorithms, big data algorithms, dynamic network analysis, clustering techniques, predictive modeling based on both initial and updated conditions, Bayesian and other statistical methods; and decision software to optimize collection of samples and contextual data that may be based on multi-criteria decision-making or other algorithms.
4. The system of claim 1 further comprising: software that controls valves to send sample streams to real time assays such as, but not limited to, LOC, POC and other real time analyzers, based on timers or decision-making software; software that controls valves to send sample streams to sample optimization chambers that contain specific reagents to optimize laboratory or on-chip analysis; and software that receives the results of real time assays from LOC, POC and other real time analyzers, and incorporates these results into further decisions and an annotated timeline.
5. The system of claim 1 further comprising: Hardware with active, computer controlled valves, sending samples to storage devices on micro- and milli-fluidic chips; sample distribution within storage devices managed with passive, hydrophobic valves; sample protection with superhydrophilic chemistry used extensively on sample contacting surfaces to prevent sample adsorption and absorption; sample protection within sample storage areas by using superhydrophobic chemistry and limiting this chemistry to only the hydrophobic valves and non-sample contacting areas to prevent sample adsorption and absorption; and highly absorbent material to contain leaks, preventing personnel or environmental contamination.
6. The system of claim 1 further comprising: sample storage that includes sample protection and optimization with addition of sample protectants including, but not limited to, protease, DNase, RNase inhibitors, anti-oxidants, anticoagulants, cryoprotectants such as trehalose, sample optimizers, for example ethylenediamine tetraacetic acid (EDTA) for mass spectrometry of lipids and metabolites; addition of reagents and sample protectants to samples with eductors, separate reagent streams or deposition of lyophilized reagents into wells during manufacture; and use of surface coatings or bulk device materials that limit the diffusion of gases or water vapor to reduce sample contamination by dissolved gasses or sample volume loss by evaporation.
7. The system of claim 1, further comprising: sample storage chambers with a tubular geometry, to allow linear filling of sample storage devices to optimize sample filling and emptying avoiding bubbles and sample break up; strategically placed sensors that detect filling at discrete points in the tubular sample compartments, allowing flow rate calculation and time stamping of sample start and end times for each sample; and strategic placement of ports to allow automated surface chemistry deposition, and efficient sample removal by automated, high throughput devices.
8. The system of claim 1, further comprising: computer software that tracks sample movement and other performance metrics to detect system component failure, and issues local and/or remote alarms to system managers; and computer software that manages a refrigeration module to prevent sample spoilage, along with issuing warnings when temperature exceeds a safe limit.
Description
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028] Optimally, the data from each patient should be given to the patient and caregivers with permissions. Using de-identification techniques data from many patients would help researchers to discover diagnostic and therapeutic leads.
DETAILED DESCRIPTION OF THE INVENTION
[0029] The system operation starts with sample collection using available methods of sampling to gather “liquid biopsies” of complex systems. For example, well established methods to sample blood, bile, lymph, wounds, tissues and organs and their secretions include microdialysis, iontophoresis, microneedles and open flow microperfusion. Intact fluids are easily sampled, once access is obtained. These include integumentary interstitial fluid, urine, sweat, tears, cerebrospinal fluid (CSF), intraocular fluid, prostatic secretions, lung fluids (sputum, pulmonary edema, hemorrhage), gastrointestinal fluids (saliva, secretions from the esophagus, stomach, biliary system, small and large intestine, pancreas), ascites, pericardial and pleural effusion, joint fluids, and edema fluid from multiple sites. Skin layers (epidermis, dermis, etc.) are particularly accessible because of peripheral location. Non-traditional fluids such as solvated exhaled breath condensate can also be collected. In one possible embodiment (
[0030] A variety of molecular and cellular components can be extracted from fluidic or solvated samples. Molecular, micro- and macroscopic components ranging from the smallest ions to the largest biomolecules, to exosomes, virus, bacteria, fungi, solid blood components such as platelets, red and white cells and cells from bone marrow and spleen, can all be sampled. In short, any soluble or non-soluble entity that can be carried away of the body with a carrier fluid or added to carrier fluid ex vivo or trapped in a hydrogel or tissue embedded permeable capsule and irrigated out can be collected by the current invention.
[0031] With portable and/or wearable systems, sampling can potentially occur over time frames from seconds to years, within or without a medical environment. Power for operation can be AC or DC current, from line supply or battery, solar, wind, water etc.
[0032] Sample collection is driven by one or more pumps. The system can use many other types of pumps with many types of force generation. A few examples include syringe pumps, peristaltic pumps, positive pressure, negative pressure, rotary, centrifugal, impeller, bubble generating, membrane/diaphragm driven, ultrasonic, electrophoretic, osmotic and many others. All can be used by this system singly or in combination.
[0033] The fluidic part of the invention is a hybrid system taking samples both for later analysis and for immediate assay. Stored samples will be later analyzed in a laboratory environment with quality control (QC). To generate real time assay results, the system will share sample fluid from the sample stream by using valves to divert the sample stream to Lab-on-a-Chip (LOC), Point-of-Care (POC) or other real time portable assay technologies. There are multiple advantages of this “assay now/assay later” combination within the invention: (1) Any researcher or device developer can easily couple their real time assay device to this system to compare their assay results (obtained in real world patients and scenarios) to the simultaneously stored sample results that benefit from processing in QC laboratories. This will accelerate validation of LOC devices. (2) a wide range of analytic technologies can be used to process the stored samples, such as protein antibody arrays, polymerase chain reaction, mass spectroscopy, chromatography etc. This range of assays far exceeds the capability of any LOC or POC device. This will allow researchers to augment their LOC assays with newly discovered molecules as needed, to improve their effectiveness. (3) The stored samples are batch handled and analyzed at the same time, by the same laboratory, with the same machine settings, standards and controls. This makes the results comparable from one sample to another. This is crucial for studies of dynamic systems over time. (3) Due to the computing power of this invention, the clinical data, plus the real time assay results can also interact with predictive and diagnostic models in real time to demonstrate the potential value of both the assays and the data analytics in a real world setting. The stored samples can help with discovery of new target molecules for future advances.
[0034] In one embodiment (
[0035] In one embodiment of the stored sample module (
[0036] Surface chemistry is a very important component of the current invention. Passive valves are used to distribute the fluid in the storage module; these are hydrophobic valves. These operate in this invention as follows: Fluid enters the sample collection cartridge 105 through an entry channel 106. When the fluid reaches a bend in the channel, 107, flow is directed upward into the first channel 108. Fluid flows through 108 and fills the first sample well 109. This occurs due to 3 factors: (1) the channel 108 is hydrophilic, enhancing capillary flow, (2) the channel 108 has a larger cross sectional area than channel 110 (see Inset A), favoring flow, and (3) the surfaces of the smaller channel 110 and part of the larger channel 111 (see Inset A) are superhydrophobic, impeding downstream flow, and favoring flow into the channel 108, and up into the first well 109.
[0037] Once the sample well 109 is filled, increasing pressure is created in the fluid channels 108 and 110 by continued incoming flow through entry channel 106. This back pressure forces fluid through the superhydrophobic valve 112 and rightward toward the second well channels. Once the superhydrophobic valve 112 is broken, the channel pressure falls (this is the nature of hydrophobic valves). After the second well fills, superhydrophobic valve 113 is opened by back pressure and the cycle repeats for the third and any further downstream wells.
[0038] GAS MANAGEMENT: As the sample wells fill, air escapes from the air vents 114. The geometry of the air vents 114 is narrow and their surfaces are superhydrophobic. This prevents fluid that is flowing along the superhydrophilic surfaces of the sample well from entering the air vent. Such fluid entry would foul the air vent, trapping a bubble, and creating a reduced sample size in the sample well. Pressure from bubble compression can also break the air vent hydrophobic valve, creating a leak. The superhydrophobic coating of the air escape valves 114 inhibits bubble trapping at the air outflow. Note that the air escape vents do not contact sample so they can have larger superhydrophobic areas without sample compromise.
[0039] Entry holes and ports can be on any surface. For this embodiment (
[0040] The shape of wells that store samples is important. The wells can be straight or curved, in one or more planes. However, tubular wells are preferred, as shown in 109 and the two other wells 116. Their tubular shape, combined with a superhydrophilic surface chemistry promotes a smooth, linear fill that is bubble free. The wells also empty with the same smooth removal pattern upon sample extraction and are completely emptied by automated pipetting. Furthermore, tubular wells provide spaces for detector placements that yield confirm system functioning and allow the calculation of approximate flow rates in the storage module 105 (see
[0041] Channel sizes can range from nanometer to millimeter size. In this embodiment, they are 0.5 mm diameter to make injection molding feasible. Smaller than this requires micro-computer numerical control (μCNC) for mold making, which is considerably more expensive for mass production.
[0042] Although many hydrophobic valves have been widely published, including in our early work (Yang B et al., Int. J. Nonlinear Sci Numerical Sim., 2002; 3:3-4), these rely on the hydrophobicity of the bulk material, which are usually polymers. This has disadvantages. First, it does not work well with less hydrophobic device materials. Second, hydrophobic surfaces adsorb many biomolecules, particularly proteins and lipid soluble molecules. The large surface area to volume ratio in microdevices with hydrophobic surfaces makes this a severe problem with sampling biofluids for example. Hydrophobic surface area must be carefully minimized. This problem was solved in the current invention by using superhydrophobic chemistry on surfaces (static water contact angle above 150° and contact angle hysteresis less than 5°), and exerting strict control of chemistry placement. In this way, the surface area that is hydrophobic can be reduced while the high wetting angle creates a higher energy barrier, maintaining good valve function with smaller areas of hydrophobicity.
[0043] Hydrophilic surfaces will adsorb proteins and lipid soluble molecules to some degree. Given the very small sample size and the need to measure low concentration molecules, combined with the high surface area to volume ratio in microdevices, even hydrophilic surfaces are a problem with analyte loss. This was solved in this invention by using so-called “stealth” chemistry to create superhydrophilic surfaces (static water contact angle<5° and protein adsorption<5 ng/cm.sup.2). These surfaces are used throughout the device, except for the very small areas devoted to the hydrophobic valves.
[0044] Alignment pins 117 assure accurate alignment with the mating BOTTOM PIECE of the sampling cartridge.
[0045] One embodiment of the bottom piece (
[0046] One method of system monitoring using non-contact detectors (
[0047] A simplified scheme (
[0048] Details of one possible embodiment of sample sharing are shown (
[0049] Once the waste well 135 is filled, the pressure on the hydrophobic valve 136 increases and the hydrophobic valve 136 opens, allowing the fresh sample to flow into Assay 2. This cycle repeats until all the assays are filled. Note that the waste well sample sizes increase 137 because more of the old sample is left in the tubing due to longer path lengths for the later samples. The waste wells must be bigger for the later assays.
[0050] Some samples require reagents mixed in with them. This can be done with active pumping of a reagent into the sample stream (not shown). It can also be done with passive reagent addition. One embodiment is shown (
[0051] The reasons for reagent addition are many. In some cases, strict attention must be paid to the sample type and the assay(s) that will analyze the sample. Many samples have fragile or labile molecules, cells or other components. These must, in some cases have chemical protectants added to them for safe storage. This may include, but not be limited to, DNase or RNase inhibitors to preserve nucleic acids, protease inhibitors to preserve proteins, anti-oxidants, cryoprotectants such as trehalose for exosomes and other analytes such as proteins, cellular cryoprotectants such as dimethylsulfoxide (DMSO), anti-coagulants to prevent clotting, optimization of anticoagulation with EDTA for lipidomic and metabolomic mass spectrography, etc.
[0052] Since the components of the fluidic system are amenable to miniaturization, and computer components continue to shrink while preserving memory and processor power, the system can be made portable or wearable. One embodiment of a wearable or partially wearable portable system is shown (
[0053] The basic system (
[0054] A more sophisticated system (
[0055] In a high resource setting, an upgraded version (
[0056] An embodiment of a miniaturized refrigeration module (
[0057] One embodiment uses a Peltier chip cooling. Heat removal from the Peltier is active in this embodiment. However, it can be augmented or replaced with passive cooling using ice or cold packs. For active heat removal there is a fan 150, atop cooling fins 151, attached to a vapor chamber 152 for rapid heat dissipation. Note that vacuum chambers spread heat with extreme efficiency, markedly increasing the cooling surface area and are ideal for refrigeration efficiency. Under the vapor chamber lies a Peltier thermoelectric chip with the hot side up 153. The chamber is sealed with polyurethane foam 154. Heat is removed from the chamber by a hollow copper pipe with capped ends 155.
[0058] A preferred embodiment is scaled down and requires less power (
[0059]
[0060] Some examples of data that have shown (or may have) potential in Al but are not systematically collected nor included in the standard EMR include: Data from vibration sensors in hospital beds can detect patient fall risk by patterns of movement. Patient movements can also detect oversedation, undersedation, delirium, escape risk and falls. Weaning patient from mechanical ventilation is a haphazard art, and essential to prevent tracheostomy, chronic long-term care and debilitation. Data from ventilators on lung performance, weaning time, and mode can be used to construct Al optimized weaning. Ventilator data can also detect worsening of lung stiffness seen in acute respiratory distress syndrome (ARDS), as seen in severe COVID-19 and other forms of sepsis. Delirium can be a devastating problem in the critically ill. New monitoring technology such as high density electroencephalography (EEG) and cerebral near infrared spectroscopy (NIRS) may detect early, and categorize delirium. Total body infrared imaging may detect early infection (fever) and peripheral vasoconstriction (hypovolemic shock), unaddressed pain, hypermetabolism (sepsis) etc. There are many other potential non-obvious data sources that can, taken together, expand the data spectrum for data analytics.
[0061] In the patient environment, and in any other arrangement where patient data could be at risk, multiple layers of security must be added. There are secure computing strategies wherein predictive disease models work with the patient's individual data as model parameters but never remove the data from the bedside. There are other protocols where patient data is used by a network component, then immediately erased. Many other solutions are being developed.
[0062] A concept for a typical data-rich display of the accumulated data that will allow a molecular learning process to begin is shown (